Literature DB >> 24313898

Cardiac and proinflammatory markers predict prognosis in cirrhosis.

Signe Wiese1, Christian Mortensen, Jens P Gøtze, Erik Christensen, Ove Andersen, Flemming Bendtsen, Søren Møller.   

Abstract

BACKGROUND & AIMS: Inflammation and cardiac dysfunction plays an important role in the development of complications leading to increased mortality in patients with cirrhosis. Novel cardiac markers such as prohormone of ANP (proANP), copeptin and high-sensitivity troponin T (hs-TnT) and proinflammatory markers including soluble urokinase-type plasminogen activator receptor (suPAR) and high-sensitive C-reactive protein (hs-CRP) are related to these complications. We aimed to investigate if cardiac and proinflammatory markers are related to severity of liver disease, cardiac and haemodynamic changes, and long-term survival.
METHODS: One hundred and ninety-three stable cirrhotic patients (Child class: A = 46; B = 97; C = 50) had a full haemodynamic investigation performed with measurement of splanchnic and systemic haemodynamics and measurement of circulating levels of proBNP, proANP, copeptin, hs-TnT, LBP, IL 6, IL 8, IP 10, VEGF, hs-CRP and suPAR.
RESULTS: Soluble urokinase-type plasminogen activator receptor soluble urokinase-type plasminogen activator receptor, hs-CRP, and hs-TnT were significantly different throughout the Child classes (P < 0.01; P < 0.01; P < 0.02). All markers except copeptin correlated with indicators of disease severity in cirrhosis; ProANP and suPAR correlated with hepatic venous pressure gradient (r = 0.24 and r = 0.34; P < 0.001) and systemic vascular resistance (r = -0.24 and r = -0.33; P < 0.001). Cardiac (proANP, hs-TnT; P < 0.01) and proinflammatory (hs-CRP, suPAR; P < 0.05) markers were associated with mortality in a univariate Cox analysis, however, the strongest predictors of mortality in a multivariate Cox analysis were hs-TnT, ascites and hepatic venous pressure gradient (reg.coeff.: 0.34, P < 0.001; 0.16, P < 0.001; 0.06, P = 0.04).
CONCLUSION: Markers of cardiac dysfunction and inflammation are significantly associated with disease severity, degree of portal hypertension and survival in cirrhosis. In particular, hs-TnT and suPAR seem to contain prognostic information.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic liver disease; cirrhotic cardiomyopathy; inflammation; portal hypertension

Mesh:

Substances:

Year:  2014        PMID: 24313898     DOI: 10.1111/liv.12428

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  29 in total

1.  Cirrhosis-related changes in left ventricular function and correlation with the model for end-stage liver disease score.

Authors:  Xiaopeng Li; Shanshan Yu; Lu Li; Donggang Han; Shejiao Dai; Ya Gao
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.

Authors:  Suehana Rahman; Susan V Mallett
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Congestive hepatopathy: Differentiating congestion from fibrosis.

Authors:  Alexander Lemmer; Lisa VanWagner; Daniel Ganger
Journal:  Clin Liver Dis (Hoboken)       Date:  2018-01-02

Review 4.  Cirrhotic Cardiomyopathy: A New Clinical Phenotype.

Authors:  Luis Otávio Cardoso Mocarzel; Mariana Macedo Rossi; Bruna de Mello Miliosse; Pedro Gemal Lanzieri; Ronaldo Altenburg Gismondi
Journal:  Arq Bras Cardiol       Date:  2017-06       Impact factor: 2.000

5.  Redefining Cirrhotic Cardiomyopathy for the Modern Era.

Authors:  Manhal Izzy; Lisa B VanWagner; Grace Lin; Mario Altieri; James Y Findlay; Jae K Oh; Kymberly D Watt; Samuel S Lee
Journal:  Hepatology       Date:  2019-10-11       Impact factor: 17.425

Review 6.  Cirrhotic Multiorgan Syndrome.

Authors:  Søren Møller; Flemming Bendtsen
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

7.  Inflammation, psychiatric symptoms, and opioid use are associated with pain and disability in patients with cirrhosis.

Authors:  Shari S Rogal; Klaus Bielefeldt; Ajay D Wasan; Francis E Lotrich; Susan Zickmund; Eva Szigethy; Andrea F DiMartini
Journal:  Clin Gastroenterol Hepatol       Date:  2014-11-05       Impact factor: 11.382

8.  NT-proBNP and Echocardiographic Parameters in Liver Cirrhosis - Correlations with Disease Severity.

Authors:  Alexandru Radu Mihailovici; Ionuț Donoiu; Dan Ionuț Gheonea; Oana Mirea; Georgică Costinel Târtea; Maria Buşe; Veronica Calborean; Cosmin Obleagă; Vlad Pădureanu; Octavian Istrătoaie
Journal:  Med Princ Pract       Date:  2019-04-16       Impact factor: 1.927

Review 9.  Diastolic dysfunction in cirrhosis.

Authors:  Søren Møller; Signe Wiese; Hanne Halgreen; Jens D Hove
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

Review 10.  Cirrhotic cardiomyopathy.

Authors:  Luis Ruiz-del-Árbol; Regina Serradilla
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.